We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Hinge Health Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
HNGE combines strong growth and profitability with AI-driven efficiency supporting scalability and expansion.
Hinge Health posted 51% revenue growth, high retention, and growing enterprise penetration in 2025.
HNGE faces 2026 slowdown, margin pressure, and reliance on engagement over pricing for growth.
Hinge Health (HNGE - Free Report) is likely to continue its exceptional growth and profitability in 2026, supported by AI-driven efficiency and strong commercial momentum. However, a projected slowdown, reliance on engagement-driven growth and limited pricing upside highlight emerging execution risks, even as the company scales its platform.
Shares of this Zacks Rank #2 (Buy) company have lost 17.1% year to date compared with the industry's 25.4% decline. The S&P 500 Index has fallen 4.9% in the same time frame.
HNGE, with a market capitalization of $3 billion, operates a digital musculoskeletal (MSK) care platform designed to transform the treatment of arthritis, back pain, joint injuries, and post-surgical rehabilitation. Earnings are projected to decline 29.4% in 2026 but rebound 15.9% in 2027, supported by strong revenue growth across both years.
Image Source: Zacks Investment Research
Factors Favoring HNGE’s Growth
Exceptional Growth With Best-in-Class Profitability Metrics: Hinge Health delivered a robust performance with 51% full-year revenue growth alongside a 31% free cash flow margin in 2025, achieving a Rule of 40 score above 80%. This rare combination of high growth and profitability positions the company among a small cohort of elite tech-enabled healthcare firms.
Strong billings growth (44%) and improving operating margins (20%) highlight scalability. This performance demonstrates that HNGE’s model is not only high-growth but also structurally efficient, enabling sustained reinvestment without compromising profitability.
AI-Driven Operating Leverage Enhancing Scalability: Hinge Health’s AI integration is materially improving efficiency across care delivery and operations. The company served 47% more members while keeping care team costs flat, driven by automation and tools like its AI assistant “Robin.”
R&D productivity has doubled, and operating costs have declined significantly as a percentage of revenues. These gains indicate a structurally scalable model where incremental revenues carry high contribution margins. Continued AI deployment across clinical, product and administrative workflows positions HNGE to expand margins further while maintaining service quality.
Strong Commercial Momentum and Expanding Market Penetration: The company added 4.8 million net new contracted lives in 2025, reaching nearly 24.6 million, with enterprise penetration including 53% of Fortune 100 clients. High retention (97%) and net dollar retention above 110% reflect strong client stickiness and expansion potential.
Competitive displacement wins further validate product superiority. Partnerships with more than 60 ecosystem players (health plans, PBMs) enhance distribution leverage. This robust commercial engine supports predictable growth, with a substantial untapped market remaining within the nearly 215 million addressable population.
Downsides for HNGE
Potential Growth Deceleration in 2026: Despite strong historical performance and strong management guidance of nearly 25% revenue growth in 2026, the company’s earnings are anticipated to decline almost 30% in 2026, reflecting margin pressure.
The anticipated revenue growth in 2026 is a notable deceleration from 51% in 2025. This reflects a more mature growth base and conservative assumptions around yield and pricing. While still robust, the slowdown may impact valuation expectations, particularly for investors accustomed to hypergrowth. Sustaining premium multiples will likely depend on continued margin expansion and successful execution of new growth vectors such as HingeSelect and adjacent product expansion.
Dependence on Yield Improvements and Engagement Dynamics: Revenue growth is increasingly tied to improvements in yield (member engagement rates) rather than pricing, which remains largely flat. While 2025 saw strong yield gains, 2026 guidance suggests no further improvement, highlighting uncertainty in sustaining this momentum.
Since the business model relies on converting eligible lives into active users, any plateau in engagement or reduced effectiveness of enrollment strategies could limit billings growth and dampen revenue expansion.
Pricing Constraints and Limited Near-Term Monetization Levers: Average selling prices are expected to remain largely flat in 2026, as the company prioritizes adoption of its engagement-based pricing model and client retention. While this supports long-term relationships, it limits near-term revenue upside from pricing.
Growth must therefore come from volume (lives and engagement), increasing reliance on execution. Transitioning billing models introduces timing differences in cash flows, which could create short-term variability in financial performance.
The Zacks Consensus Estimate for 2026 revenues is pegged at $739 million, indicating a 25.7% increase from the 2025 level.
The consensus mark for adjusted earnings per share is pinned at $1.85 for 2026.
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space are Veeva Systems (VEEV - Free Report) , Align Technology (ALGN - Free Report) and Cardinal Health (CAH - Free Report) .
Veeva Systems, currently carrying a Zacks Rank #2, has an estimated long-term growth rate of 23.8%. VEEV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva System’s shares have declined 22.6% compared with the industry’s 25.4% decrease year to date.
Align Technology, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.16%.
ALGN’s shares have climbed 9.8% against the industry’s 4.5% decline so far this year.
Cardinal Health, currently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.
CAH’s shares have gained 2.2% against the industry’s 4.5% decline so far this year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add Hinge Health Stock to Your Portfolio Now
Key Takeaways
Hinge Health (HNGE - Free Report) is likely to continue its exceptional growth and profitability in 2026, supported by AI-driven efficiency and strong commercial momentum. However, a projected slowdown, reliance on engagement-driven growth and limited pricing upside highlight emerging execution risks, even as the company scales its platform.
Shares of this Zacks Rank #2 (Buy) company have lost 17.1% year to date compared with the industry's 25.4% decline. The S&P 500 Index has fallen 4.9% in the same time frame.
HNGE, with a market capitalization of $3 billion, operates a digital musculoskeletal (MSK) care platform designed to transform the treatment of arthritis, back pain, joint injuries, and post-surgical rehabilitation. Earnings are projected to decline 29.4% in 2026 but rebound 15.9% in 2027, supported by strong revenue growth across both years.
Image Source: Zacks Investment Research
Factors Favoring HNGE’s Growth
Exceptional Growth With Best-in-Class Profitability Metrics: Hinge Health delivered a robust performance with 51% full-year revenue growth alongside a 31% free cash flow margin in 2025, achieving a Rule of 40 score above 80%. This rare combination of high growth and profitability positions the company among a small cohort of elite tech-enabled healthcare firms.
Strong billings growth (44%) and improving operating margins (20%) highlight scalability. This performance demonstrates that HNGE’s model is not only high-growth but also structurally efficient, enabling sustained reinvestment without compromising profitability.
AI-Driven Operating Leverage Enhancing Scalability: Hinge Health’s AI integration is materially improving efficiency across care delivery and operations. The company served 47% more members while keeping care team costs flat, driven by automation and tools like its AI assistant “Robin.”
R&D productivity has doubled, and operating costs have declined significantly as a percentage of revenues. These gains indicate a structurally scalable model where incremental revenues carry high contribution margins. Continued AI deployment across clinical, product and administrative workflows positions HNGE to expand margins further while maintaining service quality.
Strong Commercial Momentum and Expanding Market Penetration: The company added 4.8 million net new contracted lives in 2025, reaching nearly 24.6 million, with enterprise penetration including 53% of Fortune 100 clients. High retention (97%) and net dollar retention above 110% reflect strong client stickiness and expansion potential.
Competitive displacement wins further validate product superiority. Partnerships with more than 60 ecosystem players (health plans, PBMs) enhance distribution leverage. This robust commercial engine supports predictable growth, with a substantial untapped market remaining within the nearly 215 million addressable population.
Downsides for HNGE
Potential Growth Deceleration in 2026: Despite strong historical performance and strong management guidance of nearly 25% revenue growth in 2026, the company’s earnings are anticipated to decline almost 30% in 2026, reflecting margin pressure.
The anticipated revenue growth in 2026 is a notable deceleration from 51% in 2025. This reflects a more mature growth base and conservative assumptions around yield and pricing. While still robust, the slowdown may impact valuation expectations, particularly for investors accustomed to hypergrowth. Sustaining premium multiples will likely depend on continued margin expansion and successful execution of new growth vectors such as HingeSelect and adjacent product expansion.
Dependence on Yield Improvements and Engagement Dynamics: Revenue growth is increasingly tied to improvements in yield (member engagement rates) rather than pricing, which remains largely flat. While 2025 saw strong yield gains, 2026 guidance suggests no further improvement, highlighting uncertainty in sustaining this momentum.
Since the business model relies on converting eligible lives into active users, any plateau in engagement or reduced effectiveness of enrollment strategies could limit billings growth and dampen revenue expansion.
Pricing Constraints and Limited Near-Term Monetization Levers: Average selling prices are expected to remain largely flat in 2026, as the company prioritizes adoption of its engagement-based pricing model and client retention. While this supports long-term relationships, it limits near-term revenue upside from pricing.
Growth must therefore come from volume (lives and engagement), increasing reliance on execution. Transitioning billing models introduces timing differences in cash flows, which could create short-term variability in financial performance.
Hinge Health Inc. Price
Hinge Health Inc. price | Hinge Health Inc. Quote
HNGE’s Estimate Trend
The Zacks Consensus Estimate for 2026 revenues is pegged at $739 million, indicating a 25.7% increase from the 2025 level.
The consensus mark for adjusted earnings per share is pinned at $1.85 for 2026.
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space are Veeva Systems (VEEV - Free Report) , Align Technology (ALGN - Free Report) and Cardinal Health (CAH - Free Report) .
Veeva Systems, currently carrying a Zacks Rank #2, has an estimated long-term growth rate of 23.8%. VEEV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva System’s shares have declined 22.6% compared with the industry’s 25.4% decrease year to date.
Align Technology, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.16%.
ALGN’s shares have climbed 9.8% against the industry’s 4.5% decline so far this year.
Cardinal Health, currently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.
CAH’s shares have gained 2.2% against the industry’s 4.5% decline so far this year.